메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Seo Hyeonji (Department of Infectious Diseases Asan Medical Center University of Ulsan College of Medicine Seoul) Kim Haein (Department of Infectious Diseases Asan Medical Center University of Ulsan College of Medicine Seoul) Bae Seongman (Department of Infectious Diseases Asan Medical Center University of Ulsan College of Medicine Seoul) Park Seonghee (Department of Infectious Diseases Asan Medical Center University of Ulsan College of Medicine Seoul) Chung Hyemin (Department of Infectious Diseases Asan Medical Center University of Ulsan College of Medicine Seoul) Sung Heungsup (Department of Laboratory Medicine Asan Medical Center University of Ulsan College of Medicine Seoul) Jung Jiwon (Department of Infectious Diseases Asan Medical Center University of Ulsan College of Medicine Seoul) Kim Min-Jae (Department of Infectious Diseases Asan Medical Center University of Ulsan College of Medicine Seoul) Kim Sung-Han (Department of Infectious Diseases Asan Medical Center University of Ulsan College of Medicine Seoul) Lee Sang-Oh (Department of Infectious Diseases Asan Medical Center University of Ulsan College of Medicine Seoul) Choi Sang-Ho (Department of Infectious Diseases Asan Medical Center University of Ulsan College of Medicine Seoul) Kim Yang Soo (Department of Infectious Diseases Asan Medical Center University of Ulsan College of Medicine Seoul) Son Ki Young (Department of Family Medicine Asan Medical Center University of Ulsan College of Medicine Seoul Kor) Chong Yong Pil (Department of Infectious Diseases Asan Medical Center University of Ulsan College of Medicine Seoul)
저널정보
대한감염학회 Infection and Chemotherapy Infection and Chemotherapy 제54권 제1호
발행연도
2022.3
수록면
102 - 113 (12page)
DOI
10.3947/ic.2021.0142

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background This study aimed to evaluate whether fluvoxamine reduces clinical deterioration in adult patients with mild to moderate coronavirus disease 2019 (COVID-19), and to identify risk factors for clinical deterioration in patients admitted to a community treatment center (CTC). Materials and Methods A randomized, placebo-controlled trial was conducted in a CTC, in Seoul, Korea from January 15, 2021, to February 19, 2021. Symptomatic adult patients with positive results of severe acute respiratory syndrome coronavirus 2 real time-polymerase chain reaction within 3 days of randomization were assigned at random to receive 100 mg of fluvoxamine or placebo twice daily for 10 days. The primary outcome was clinical deterioration defined by any of the following criteria: oxygen requirement to keep oxygen saturation over 94.0%, aggravation of pneumonia with dyspnea, or World Health Organization clinical progression scale 4 or greater. Results Of 52 randomized participants [median (interquartile range) age, 53.5 (43.3 - 60.0) years; 31 (60.0%) men], 44 (85.0%) completed the trial. Clinical deterioration occurred in 2 of 26 patients in each group (P >0.99). There were no serious adverse events in either group. Clinical deterioration occurred in 15 (6.0%) of 271 patients admitted to the CTC, and all of them were transferred to a hospital. In multivariate analysis, age between 55 and 64, fever and pneumonia at admission were independent risk factors for clinical deterioration. Conclusion In this study of adult patients with symptomatic COVID-19 who were admitted to the CTC, there was no significant differences in clinical deterioration between patients treated with fluvoxamine and placebo (ClinicalTrials.gov Identifier: NCT04711863).

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0